Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy

被引：1

作者：

Hernyak, Marcell ^{[1
,2
]}

Toth, Laszlo Imre ^{[1
,2
]}

Csiha, Sara ^{[1
]}

Molnar, Agnes ^{[1
]}

Lorincz, Hajnalka ^{[1
]}

Paragh, Gyorgy ^{[1
]}

Harangi, Mariann ^{[1
,3
,4
]}

Sztanek, Ferenc ^{[1
]}

机构：

[1] Univ Debrecen, Fac Med, Dept Internal Med, Div Metab, H-4032 Debrecen, Hungary

[2] Univ Debrecen, Doctoral Sch Hlth Sci, H-4032 Debrecen, Hungary

[3] Univ Debrecen, Inst Hlth Stud, Fac Hlth Sci, H-4032 Debrecen, Hungary

[4] Univ Debrecen, ELKH UD Vasc Pathophysiol Res Grp 11003, H-4032 Debrecen, Hungary

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 24期

关键词：

alpha-lipoic acid; diabetic sensorimotor neuropathy; endothelial dysfunction; kallistatin; type; 2; diabetes; oxidative stress; ASYMMETRIC DIMETHYLARGININE; INHIBITS ANGIOGENESIS; PERIPHERAL NEUROPATHY; OXIDATIVE STRESS; INFLAMMATION; INJURY; ANTIOXIDANT; DYSFUNCTION; MECHANISMS; APOPTOSIS;

D O I：

10.3390/ijms252413276

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Diabetic sensorimotor neuropathy (DSPN) is strongly associated with the extent of cellular oxidative stress and endothelial dysfunction in type 2 diabetes (T2DM). Alpha-lipoic acid (ALA) attenuates the progression of DSPN through its antioxidant and vasculoprotective effects. Kallistatin has antioxidant and anti-inflammatory properties. We aimed to evaluate changes in kallistatin levels and markers of endothelial dysfunction in patients with T2DM and DSPN following six months of treatment with 600 mg/day of ALA. A total of 54 patients with T2DM and DSPN and 24 control patients with T2DM but without neuropathy participated in this study. The serum concentrations of kallistatin, ICAM-1, VCAM-1, oxLDL, VEGF, ADMA, and TNF-alpha were measured by an ELISA. Peripheral sensory neuropathy was assessed with neuropathy symptom questionnaires and determination of the current perception threshold. After ALA treatment, the level of kallistatin significantly decreased, as well as the levels of TNF-alpha and ADMA. Changes in kallistatin levels were positively correlated with changes in oxLDL. The improvement in DSPN symptoms following ALA treatment showed a positive correlation with changes in kallistatin, VEGF, oxLDL, and ADMA levels. Based on our results, kallistatin could represent a potential new biomarker for assessing therapeutic response during ALA treatment in patients with DSPN.

引用

页数：14

共 40 条

[1] Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus [J].

Abbasi, F ;

Asagmi, T ;

Cooke, JP ;

Lamendola, C ;

McLaughlin, T ;

Reaven, GM ;

Stuehlinger, M ;

Tsao, PS .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (10) :1201-+

[2] Development and validity testing of the neuropathy total symptom score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy [J].

Bastyr, EJ ;

Price, KL ;

Bril, V .

CLINICAL THERAPEUTICS, 2005, 27 (08) :1278-1294

[3] Association of kallistatin with carotid intima-media thickness in women with polycystic ovary syndrome [J].

Calan, Mehmet ;

Guler, Asli ;

Unal Kocabas, Gokcen ;

Alarslan, Pinar ;

Bicer, Merve ;

Imamoglu, Cetin ;

Yuksel, Arif ;

Bozkaya, Giray ;

Bilgir, Oktay .

MINERVA ENDOCRINOLOGICA, 2018, 43 (03) :236-245

[4] The Importance of Rare Subtypes in Diagnosis and Treatment of Peripheral Neuropathy A Review [J].

Callaghan, Brian C. ;

Price, Raymond S. ;

Chen, Kevin S. ;

Feldman, Eva L. .

JAMA NEUROLOGY, 2015, 72 (12) :1510-1518

[5] Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications [J].

Caturano, Alfredo ;

D'Angelo, Margherita ;

Mormone, Andrea ;

Russo, Vincenzo ;

Mollica, Maria Pina ;

Salvatore, Teresa ;

Galiero, Raffaele ;

Rinaldi, Luca ;

Vetrano, Erica ;

Marfella, Raffaele ;

Monda, Marcellino ;

Giordano, Antonio ;

Sasso, Ferdinando Carlo .

CURRENT ISSUES IN MOLECULAR BIOLOGY, 2023, 45 (08) :6651-6666

[6] Kallistatin is a potent new vasodilator [J].

Chao, JL ;

Stallone, JN ;

Liang, YM ;

Chen, LM ;

Wang, DZ ;

Chao, L .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (01) :11-17

[7] Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation [J].

Chao, Julie ;

Yin, Hang ;

Yao, Yu-Yu ;

Shen, Bo ;

Smith, Robert S., Jr. ;

Chao, Lee .

HUMAN GENE THERAPY, 2006, 17 (12) :1201-1213

[8] Protective Role of Endogenous Kallistatin in Vascular Injury and Senescence by Inhibiting Oxidative Stress and Inflammation [J].

Chao, Julie ;

Guo, Youming ;

Chao, Lee .

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2018, 2018

[9] Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve [J].

Coppey, LJ ;

Gellett, JS ;

Davidson, EP ;

Dunlap, JA ;

Lund, DD ;

Yorek, MA .

DIABETES, 2001, 50 (08) :1927-1937

[10] Total neuropathy score - Validation and reliability study [J].

Cornblath, DR ;

Chaudhry, V ;

Carter, K ;

Lee, D ;

Seysedadr, M ;

Miernicki, M ;

Joh, T .

NEUROLOGY, 1999, 53 (08) :1660-1664

← 1 2 3 4 →